These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 29124994)

  • 1. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
    Farkas K; Molnár T
    Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT-P13: design, development, and place in therapy.
    Gabbani T; Deiana S; Annese V
    Drug Des Devel Ther; 2017; 11():1653-1661. PubMed ID: 28652703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of the biosimilar CT-P13.
    Yoo DH
    J Comp Eff Res; 2017 Nov; 6(8):693-712. PubMed ID: 29172717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases.
    Wook Hong S; Kim YG; Ye BD
    Immunotherapy; 2020 Jun; 12(9):609-623. PubMed ID: 32517574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W; Louis E; Danese S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.
    Gecse KB; Lakatos PL
    Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness.
    Cheon JH; Nah S; Kang HW; Lim YJ; Lee SH; Lee SJ; Kim SH; Jung NH; Park JE; Lee YJ; Jeon DB; Lee YM; Kim JM; Park SH
    Adv Ther; 2021 Aug; 38(8):4366-4387. PubMed ID: 34250583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.
    Bellinvia S; Ashraf M; Polosa R; Edwards C
    Immunotherapy; 2017 Nov; 9(14):1133-1142. PubMed ID: 29067885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CT-P13 in the treatment of rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.
    Lim KJ; Lee SJ; Kim S; Lee SY; Lee MS; Park YA; Choi EJ; Lee EB; Jun HK; Cho JM; Lee S; Kwon KS; Lim BP; Jeon MS; Shin EC; Choi YS; Fudim E; Picard O; Yavzori M; Ben-Horin S; Chang SJ
    J Crohns Colitis; 2017 May; 11(5):593-602. PubMed ID: 28453766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
    Guerra Veloz MF; Argüelles-Arias F; Castro Laria L; Maldonado Pérez B; Benítez Roldan A; Perea Amarillo R; Merino Bohórquez V; Calleja MA; Caunedo Álvarez Á; Vilches Arenas Á
    World J Gastroenterol; 2018 Dec; 24(46):5288-5296. PubMed ID: 30581277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of CT-P13: an infliximab biosimilar.
    McKeage K
    BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease.
    Ebada MA; Elmatboly AM; Ali AS; Ibrahim AM; Fayed N; Faisal AF; Alkanj S
    Int J Colorectal Dis; 2019 Oct; 34(10):1633-1652. PubMed ID: 31492986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study.
    Kang B; Lee Y; Lee K; Choi YO; Choe YH
    Inflamm Bowel Dis; 2018 Feb; 24(3):607-616. PubMed ID: 29390113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
    Mazza S; Piazza O Sed N; Conforti FS; Fascì A; Rimondi A; Marinoni B; Casini V; Ricci C; Munari F; Pirola L; Invernizzi P; Girelli C; Lupinacci G; Pastorelli L; Cavallaro F; Ferraris L; Colucci A; Amato A; Eugenio Tontini G; Vecchi M; Fiorino G; Caprioli F
    Clin Transl Sci; 2022 Jan; 15(1):172-181. PubMed ID: 34523800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.